Alzheimer’s drugs to show profit

ELAN could be well-positioned to start profiting from its anti-Alzheimer’s products over the next decade, with two of its drugs for treating the degenerative disease potentially delivering combined annual sales of around $5 billion (€4.18bn) by 2015.

Goodbody Stockbrokers has forecast that, on current market price levels, the two Alzheimer's drugs in which Elan is collaborating with Wyeth Pharmaceuticals with the production names AAB-001 and ACC-001 could generate sales of $2.7bn (€2.26bn) and $2.2bn (€1.84bn) respectively by 2015.

The two drugs are in Phase II and Phase I of development respectively and could, potentially, be approved for market within four years.